RxDoctor Payments Data

Brian Gonzalez Sanabia

Cardiovascular Disease · Ponce, PRNPI 1437649860

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.7% of the total across 359 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Boston Scientific at 42.8% of the total.

$10,026in general payments, 2019–2025

Across 359 payments — averaging $27.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Abbott$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Medtronic$1K
  • PBG Puerto Rico LLC$490
  • AstraZeneca$365
  • plus $1K from 11 others

What the payments were for

  • Travel & lodging$330%
  • Food & beverage$9,70097%
  • Education$2482%
  • Gifts$460%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific123$4,288
Abbott58$1,332
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)57$1,121
Medtronic34$1,055
PBG Puerto Rico LLC27$490
AstraZeneca12$365
Johnson & Johnson15$264
Amgen5$236
Boehringer Ingelheim4$197
E.r. Squibb & Sons, L.L.C.5$189
Bayer Puerto Rico Inc.5$120
Novartis5$107
Merck4$91
Sanofi-aventis U.S. LLC1$90
Chiesi USA, Inc.2$60
Cordis US CORP.1$18
Pfizer1$3

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,026 in reported general payments places this provider in the 80th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$14,921
FarxigaDapagliflozin Propanediol14$8,220
BrilintaTicagrelor17$7,772
Candesartan Cilexetil13$883
Rosuvastatin Calcium55$689
Metoprolol Succinate65$574
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide34$501
Atorvastatin Calcium70$485
ClopidogrelClopidogrel Bisulfate36$389
Irbesartan18$385
Losartan Potassium34$367
Nifedipine ErNifedipine13$258
Amlodipine Besylate70$245
Carvedilol33$223
Lisinopril57$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$365$15,99231 claims
PfizerEliquis$3$14,92123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →